1. Home
  2. WLII vs CGEN Comparison

WLII vs CGEN Comparison

Compare WLII & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WLII

Willow Lane Acquisition Corp. II Class A Ordinary Shares

N/A

Current Price

$10.17

Market Cap

205.1M

Sector

Finance

ML Signal

N/A

Logo Compugen Ltd.

CGEN

Compugen Ltd.

SELL

Current Price

$1.83

Market Cap

201.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WLII
CGEN
Founded
2025
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.1M
201.8M
IPO Year
2026
2001

Fundamental Metrics

Financial Performance
Metric
WLII
CGEN
Price
$10.17
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $4.80
AVG Volume (30 Days)
9.2K
★ 201.3K
Earning Date
N/A
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$55.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.14
$1.43
52 Week High
$10.29
$3.24

Technical Indicators

Market Signals
Indicator
WLII
CGEN
Relative Strength Index (RSI) 46.14 34.45
Support Level N/A N/A
Resistance Level $10.29 $2.18
Average True Range (ATR) 0.02 0.09
MACD -0.00 -0.01
Stochastic Oscillator 42.86 2.94

Price Performance

Historical Comparison
WLII
CGEN

About WLII Willow Lane Acquisition Corp. II Class A Ordinary Shares

Willow Lane Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: